GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ENSC · Jun 30, 2026

Ensysce Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]

Inspectable configuration

State dimensions

Filing0001493152-26-037817General Corporate

Operating cash generation75thOwn-history percentile · N=16

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-168.55% · OPTIONAL · VALID

Revenue growth33thOwn-history percentile · N=12

Evidence method

Yoy · gp.fundamentals.revenue

-15.10% · CORE · VALID

Operating margin69thOwn-history percentile · N=16

Evidence method

Level · gp.fundamentals.operating_margin

-221.28% · CORE · VALID

R&D intensity31thOwn-history percentile · N=16

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

212.29% · OPTIONAL · VALID

SBC intensity0thOwn-history percentile · N=16

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

0.16% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesSelf-history eligible

Jun 30, 20230/5 normalizedLevel 3 Sep 30, 20230/5 normalizedLevel 3 Dec 31, 20230/5 normalizedLevel 3 Mar 31, 20240/5 normalizedLevel 3 Jun 30, 20244/5 normalizedLevel 3 Sep 30, 20244/5 normalizedLevel 3 Dec 31, 20244/5 normalizedLevel 3 Mar 31, 20254/5 normalizedLevel 3 Jun 30, 20255/5 normalizedLevel 3 Sep 30, 20255/5 normalizedLevel 3 Dec 31, 20255/6 normalizedLevel 3 Mar 31, 20265/5 normalizedLevel 3 Jun 30, 20265/5 normalizedLevel 4

Period transition

What moved in the state?

Cash Generation Increased

Previous: -364.30%
Current: -168.55%
Delta: 195.75%

Growth Increased

Previous: -27.18%
Current: -15.10%
Delta: 12.08%

Profitability Increased

Previous: -370.68%
Current: -221.28%
Delta: 149.40%

R And D Intensity Decreased

Previous: 348.27%
Current: 212.29%
Delta: -135.98%

Sbc Intensity Decreased

Previous: 0.91%
Current: 0.16%
Delta: -0.75%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Dec 31, 2025

Similarity: 90%
Compared: 5 dimensions
Coverage: 100%

Growth 6.7 · Profitability 2.7 · Sbc Intensity 21.4 · Cash Generation 3.6 · R And D Intensity 2.7

Mar 31, 2025

Similarity: 87%
Compared: 4 dimensions
Coverage: 80%

Profitability 13.1 · Sbc Intensity 9.1 · Cash Generation 15.9 · R And D Intensity 13.1

Sep 30, 2024

Similarity: 75%
Compared: 4 dimensions
Coverage: 80%

Profitability 31.3 · Sbc Intensity 0.0 · Cash Generation 25.0 · R And D Intensity 31.3

Research Graph

Related governed research

Analogous To · ENSC state analogue 1 →Analogous To · ENSC state analogue 2 →Analogous To · ENSC state analogue 3 →Compared To · Pharmaceutical Preparations peers →Has State · Ensysce Biosciences, Inc. →Transitioned To · ENSC Fundamental State →Transitioned To · ENSC CASH_GENERATION_INCREASED →Transitioned To · ENSC GROWTH_INCREASED →Transitioned To · ENSC PROFITABILITY_INCREASED →Transitioned To · ENSC R_AND_D_INTENSITY_DECREASED →Transitioned To · ENSC SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.